Merck Price to Free Cash Flow Ratio 2010-2024 | MRK

Historical price to free cash flow ratio values for Merck (MRK) since 2010. For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Merck Price to Free Cash Flow Ratio Historical Data
Date Stock Price TTM FCF per Share Price to FCF Ratio
2024-11-01 101.88 19.74
2024-06-30 123.00 $5.16 23.83
2024-03-31 130.31 $4.34 30.05
2023-12-31 106.98 $3.59 29.80
2023-09-30 100.29 $5.17 19.39
2023-06-30 111.66 $4.26 26.22
2023-03-31 102.26 $4.43 23.10
2022-12-31 105.92 $5.79 18.31
2022-09-30 81.68 $6.03 13.56
2022-06-30 85.79 $5.70 15.06
2022-03-31 76.59 $4.84 15.81
2021-12-31 70.91 $3.42 20.75
2021-09-30 68.85 $2.67 25.83
2021-06-30 70.65 $1.29 54.79
2021-03-31 69.43 $1.43 48.68
2020-12-31 73.04 $1.25 58.22
2020-09-30 73.47 $0.16 457.19
2020-06-30 68.00 $1.38 49.11
2020-03-31 67.12 $-1.07 0.00
2019-12-31 78.72 $0.03 2615.17
2019-09-30 72.36 $1.15 62.73
2019-06-30 71.60 $0.92 78.19
2018-12-31 64.38 $3.10 20.76
2018-09-30 59.35 $3.48 17.04
2018-06-30 50.43 $2.96 17.04
2018-03-31 44.91 $1.34 33.54
2017-12-31 45.99 $2.14 21.48
2019-03-31 70.55 $0.75 94.52
2017-09-30 51.89 $1.57 33.12
2017-06-30 51.57 $3.07 16.80
2017-03-31 50.75 $2.45 20.74
2016-12-31 46.68 $3.14 14.85
2016-09-30 49.11 $3.36 14.64
2016-06-30 45.00 $3.50 12.86
2016-03-31 40.99 $3.91 10.48
2015-12-31 40.57 $3.96 10.24
2015-09-30 37.60 $2.11 17.84
2015-06-30 42.97 $2.45 17.57
2015-03-31 43.06 $2.28 18.89
2014-12-31 42.21 $2.28 18.52
2014-09-30 43.72 $3.65 11.97
2014-06-30 42.36 $3.49 12.15
2014-03-31 41.26 $3.45 11.97
2013-12-31 36.09 $3.37 10.70
2013-09-30 34.02 $2.87 11.84
2013-06-30 32.90 $2.52 13.05
2013-03-31 31.02 $2.68 11.57
2012-12-31 28.46 $2.62 10.85
2012-09-30 31.05 $3.13 9.91
2012-06-30 28.48 $3.60 7.91
2012-03-31 25.91 $3.59 7.22
2011-12-31 25.16 $3.45 7.30
2011-09-30 21.56 $3.51 6.15
2011-06-30 23.00 $2.90 7.94
2011-03-31 21.28 $3.06 6.97
2010-12-31 22.97 $2.93 7.84
2010-09-30 23.21 $2.75 8.43
2010-06-30 21.82 $1.72 12.65
2010-03-31 23.06 $0.95 24.30
2009-12-31 22.33 $0.85 26.28
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $258.042B $60.115B
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $777.423B 80.52
Novo Nordisk (NVO) Denmark $502.334B 38.34
Johnson & Johnson (JNJ) United States $385.533B 15.64
AbbVie (ABBV) United States $359.539B 18.93
Novartis AG (NVS) Switzerland $223.511B 14.86
AstraZeneca (AZN) United Kingdom $221.444B 19.73
Pfizer (PFE) United States $159.177B 10.89
Sanofi (SNY) $135.190B 12.25
Innoviva (INVA) United States $1.205B 6.69